BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30209247)

  • 1. Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report.
    Mahmoud S; Mitwally H; El Zeer HS; El Madhoun I; Khatib M
    Am J Case Rep; 2018 Sep; 19():1087-1089. PubMed ID: 30209247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin].
    Kusama M; Kaise H; Nakayama S; Ota D; Aoki T; Koyanagi Y; Matsunaga T; Nakamura Y
    Gan To Kagaku Ryoho; 2000 May; 27(5):763-6. PubMed ID: 10832449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients.
    Rosenblum RC; Twito O; Barzilay-Yoseph L; Ramaty E; Klein N; Rotman-Pikielny P
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4593-e4602. PubMed ID: 34157125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of pamidronate in three children with renal disease.
    Sellers E; Sharma A; Rodd C
    Pediatr Nephrol; 1998 Nov; 12(9):778-81. PubMed ID: 9874327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
    Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute renal failure due to severe hypercalcemia and nephrocalcinosis treated with two doses of pamidronate in an infant with Williams-Beuren syndrome.
    Baştuğ F; Nalçacıoğlu H; Baş VN; Tekatlı-Çelik B; Çetinkaya H; Yel S
    Turk J Pediatr; 2018; 60(2):210-215. PubMed ID: 30325132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
    Davenport A; Goel S; Mackenzie JC
    Scand J Urol Nephrol; 1993; 27(4):447-51. PubMed ID: 8159916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
    Trimarchi H; Lombi F; Forrester M; Elizondo C; Sawinski D; Pereyra H; Freixas E
    Nat Clin Pract Nephrol; 2006 Aug; 2(8):459-63; quiz 464. PubMed ID: 16932480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
    Kim S
    J Oncol Pharm Pract; 2019 Oct; 25(7):1787-1793. PubMed ID: 30419769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
    Quiroga García V; Cirauqui Cirauqui B; Tobey Robaina L; López Sisamon D; Hardy-Werbin M; Blanca AB; Margelí Vila M
    Anticancer Drugs; 2016 Jun; 27(5):464-9. PubMed ID: 26813866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
    McMahan J; Linneman T
    Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
    Culbert EC; Schfirin BS
    Obstet Gynecol; 2006 Sep; 108(3 Pt 2):789-91. PubMed ID: 17018504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
    Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
    Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
    Czosnowski LM; Hudson JQ; Canada RB
    Am J Med Sci; 2009 Apr; 337(4):300-1. PubMed ID: 19365180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.
    Lee DC; Lee GY
    J Toxicol Clin Toxicol; 1998; 36(7):719-21. PubMed ID: 9865241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe hypercalcemia associated with Williams syndrome successfully treated with pamidronate infusion therapy.
    Sangun O; Dundar BN; Erdogan E
    J Pediatr Endocrinol Metab; 2011; 24(1-2):69-70. PubMed ID: 21528818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
    Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
    Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of denosumab to treat refractory hypercalcemia in a peritoneal dialysis patient with immobilization and tertiary hyperparathyroidism.
    Pratt RM; West ML; Tennankore KK
    Perit Dial Int; 2020 Jan; 40(1):103-106. PubMed ID: 32063140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.